Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05094570 · ClinicalTrials.gov registry record · Phase 4
Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP
A Phase 4 study of Staphylococcus Aureus and Nasal Polyps, sponsored by University of Virginia.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05094570 is a Phase 4 study of Staphylococcus Aureus and Nasal Polyps that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 20 participants, below the 3,902-participant average among 8 other Staphylococcus Aureus trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05094570, a Phase 4 study of Staphylococcus Aureus and Nasal Polyps, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Hypothesis: The investigators hypothesize that in patients with CRSwNP who demonstrate sinus colonization with staphylococcus aureus, the administration of dupilumab will be associated with decreased staph colonization and an increase in microbial diversity. Primary Objective will be to demonstrate that dupilumab reduces staphylococcus aureus (phyla firmicutes) abundance while increasing microbial diversity in patients with CRSwNPs who are culture positive for staph aureus at enrollment. Secondary Objectives will be to correlate reduction in Staph aureus abundance and improved bacterial diversity with increased expression of anti-microbial proteins (ß-defensins1-4) and cathelicidin LL-37. In addition, the investigators will correlate improvements in microbial diversity/decreased staph abundance with clinical improvements as assessed via questionnaires and objective/subjective smell function and also as improvements in cellular/immune T2 inflammation as assessed by reduced expression of T2 cytokines/chemokines and eosinophil/eosinophil-derived proteins.
Conditions Studied
Interventions
- DRUG Dupilumab Prefilled Syringe
Study Locations (1)
Virginia
- University of Virginia Health System - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-09-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05094570
The ClinicalTrials.gov registry entry for NCT05094570 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,902-participant average among 8 other Staphylococcus Aureus trials with a reported enrollment target (99% lower). The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Staphylococcus Aureus appearing as the primary indexed condition, and to 1 intervention - of which Dupilumab Prefilled Syringe is the first listed.
NCT05094570 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT05094570 about?
NCT05094570 is a clinical study titled "Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP". Hypothesis: The investigators hypothesize that in patients with CRSwNP who demonstrate sinus colonization with staphylococcus aureus, the administration of dupilumab will be associated with decreased staph colonization and an increase in microbial diversity. Primary Objective will be to demonstrate...
What is the current status of trial NCT05094570?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2022-09-01. Estimated completion is 2026-12-31.
What conditions does trial NCT05094570 study?
This clinical trial studies the following conditions: Staphylococcus Aureus, Nasal Polyps.
What interventions are being tested in trial NCT05094570?
The interventions under investigation include: Dupilumab Prefilled Syringe (DRUG).
Who is sponsoring clinical trial NCT05094570?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05094570 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Staphylococcus Aureus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparing Single Versus Repeat NMT on the Diversity of the Neonatal Nasal Microbiome
RECRUITING · Phase 1
-
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
RECRUITING · Phase 1
-
Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Risk Factors for Linezolid Resistance in Staphylococcus Aureus
COMPLETED
-
A Prospective Cohort Pilot Study of the Clinical and Molecular Epidemiology of Staphylococcus Aureus in Pregnant Women at the Time of Group B Streptococcal Screening in a Large Urban Medical Center in Chicago, IL USA
COMPLETED · NA
-
Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.